- Light Sciences LLC
- Light Sciences Oncology Inc.
- Small Bone Innovations Inc.
- Boston Scientific Corp.
- Johnson & Johnson
- Guidant Corp.
- Allergan Inc.
- Inamed Corp.
- Medicis Pharmaceutical Corp.
- Mentor Corp.
- Animas Corp.
- LifeScan Inc.
- Genzyme Corp.
- Third Wave Technologies Inc.
- University of California, Los Angeles
- Jonsson Comprehensive Cancer Center
- Pfizer Inc.
- Schering-Plough Corp.
- Daiichi Sankyo Co. Ltd.
- Jerini AG
- Cerimon Pharmaceuticals Inc.
- Amgen Inc.
- Boehringer Ingelheim Fremont Inc.
- Immunex Corp.
- AstraZeneca PLC
- KuDOS Pharmaceuticals Ltd.
- AtheroGenics Inc.
- Avanir Pharmaceuticals Inc.
- Progenics Pharmaceuticals Inc.
- Light Sciences Oncology spins out; raises $67mm in Series A
- Small Bone Innovations closes $42.2mm Series B round
- Boston Scientific wins $27bn bid for Guidant
- J&J withdraws offer to acquire Guidant
- Allergan pays $3.1bn for Inamed
- Medicis to acquire Inamed for $2.76bn; offer withdrawn
- J&J buys Animas
- Genzyme Genetics markets Third Wave's Invader in N. America
- Genzyme licenses diagnostic rights from UCLA
- Perlegen Sciences, Pfizer sign genomics deal
- OncoMethylome, Schering-Plough in pharmacogenomics deal
- Genaissance and Sankyo enter pharmacogenomics deal
- Ipsen grosses €324mm in IPO
- Jerini AG completes its IPO
- Cerimon closes $70mm Series A round
- Amgen buys Abgenix
- AstraZeneca to buy KuDOS for $210mm
- AstraZeneca gets rights to AtheroGenics's AGI1067; terminated
- AstraZeneca, Avanir end cardiovascular disease deal
- Progenics, Wyeth develop GI compound MNTX; ends
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.